HEPA - Hepion Pharma announces clinical collaboration with HepQuant for a phase 2b NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) on Tuesday entered into a clinical collaboration with Denver, Colo.-based HepQuant, a privately held company with investigational technology for evaluating liver function and health in patients with chronic liver diseases. Hepion will incorporate HepQuant's SHUNT test, a blood-based test of liver function, into a phase 2b clinical trial that will be initiated in Q3 in subjects who have progressed to the advanced fibrosis stage of non-alcoholic steatohepatitis (NASH), a cancer of the liver. Hepion said the four month trial will evaluate three doses of its lead drug candidate, rencofilstat, in 60 presumed NASH subjects with advanced fibrosis using the HepQuant SHUNT test. HepQuant’s SHUNT test may provide a sensitive measurement of hepatic function and is designed to provide detailed information on the role rencofilstat plays in improving the liver health in NASH subjects with advanced fibrosis, HEPA said. HEPA stock +1.4% to $0.92 in early trading.

For further details see:

Hepion Pharma announces clinical collaboration with HepQuant for a phase 2b NASH trial